Amgen said they will continue to spread out their efforts on two different commercial models: biologics and biosimilars.
Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.
Sizing up his company amid a dismal annual results presentation, AstraZeneca CEO Pascal Soriot told analysts and investors: "We have become a little bit complicated and in many ways out of this, a bit conservative."
GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013.
Sales of Bristol-Myers Squibb's Plavix plunged 96% in the third quarter over the same period last year, contributing mightily to an overall 30% drop in sales of the company's products for the quarter, to $3.7 billion.
Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, the company said in a third quarter results call.
Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.
Abbott Labs reported strong second quarter sales that, though mitigated by an unfavorable exchange rate, cheered analysts and investors, with muscular growth in Humira sales a high point.
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.